BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 32822087)

  • 21. Premises among SARS-CoV-2, dysbiosis and diarrhea: Walking through the ACE2/mTOR/autophagy route.
    de Oliveira AP; Lopes ALF; Pacheco G; de Sá Guimarães Nolêto IR; Nicolau LAD; Medeiros JVR
    Med Hypotheses; 2020 Nov; 144():110243. PubMed ID: 33254549
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Gut and Parkinson's Disease: Hype or Hope?
    Scheperjans F; Derkinderen P; Borghammer P
    J Parkinsons Dis; 2018; 8(s1):S31-S39. PubMed ID: 30584161
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The gut microbiome in Parkinson's disease: A culprit or a bystander?
    Keshavarzian A; Engen P; Bonvegna S; Cilia R
    Prog Brain Res; 2020; 252():357-450. PubMed ID: 32247371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is COVID-19 a Perfect Storm for Parkinson's Disease?
    Brundin P; Nath A; Beckham JD
    Trends Neurosci; 2020 Dec; 43(12):931-933. PubMed ID: 33158605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications.
    Kalyanaraman B; Cheng G; Hardy M
    Redox Biol; 2024 May; 71():103092. PubMed ID: 38377788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological α-synuclein exacerbates the progression of Parkinson's disease through microglial activation.
    Zhang QS; Heng Y; Yuan YH; Chen NH
    Toxicol Lett; 2017 Jan; 265():30-37. PubMed ID: 27865851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation.
    George S; Brundin P
    J Parkinsons Dis; 2015; 5(3):413-24. PubMed ID: 26406122
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson's Disease.
    Caputi V; Giron MC
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29882798
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The gut in Parkinson's disease: Bottom-up, top-down, or neither?
    Leclair-Visonneau L; Neunlist M; Derkinderen P; Lebouvier T
    Neurogastroenterol Motil; 2020 Jan; 32(1):e13777. PubMed ID: 31854093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Could Perturbation of Gut Microbiota Possibly Exacerbate the Severity of COVID-19
    Vignesh R; Swathirajan CR; Tun ZH; Rameshkumar MR; Solomon SS; Balakrishnan P
    Front Immunol; 2020; 11():607734. PubMed ID: 33569053
    [No Abstract]   [Full Text] [Related]  

  • 31. From the Gut to the Brain: The Role of Enteric Glial Cells and Their Involvement in the Pathogenesis of Parkinson's Disease.
    Montalbán-Rodríguez A; Abalo R; López-Gómez L
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38279293
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Intestinal Barrier in Parkinson's Disease: Current State of Knowledge.
    van IJzendoorn SCD; Derkinderen P
    J Parkinsons Dis; 2019; 9(s2):S323-S329. PubMed ID: 31561386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dysbiosis of gut microbiota and microbial metabolites in Parkinson's Disease.
    Sun MF; Shen YQ
    Ageing Res Rev; 2018 Aug; 45():53-61. PubMed ID: 29705121
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson's Disease.
    van Kessel SP; El Aidy S
    J Parkinsons Dis; 2019; 9(s2):S359-S370. PubMed ID: 31609701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Appendix in Parkinson's Disease: From Vestigial Remnant to Vital Organ?
    Killinger B; Labrie V
    J Parkinsons Dis; 2019; 9(s2):S345-S358. PubMed ID: 31609697
    [TBL] [Abstract][Full Text] [Related]  

  • 36. COVID-19: Can the symptomatic SARS-CoV-2 infection affect the homeostasis of the gut-brain-microbiota axis?
    Chaves Andrade M; Souza de Faria R; Avelino Mota Nobre S
    Med Hypotheses; 2020 Nov; 144():110206. PubMed ID: 33254513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dysbiosis in Parkinson's disease might be triggered by certain antibiotics.
    Ternák G; Kuti D; Kovács KJ
    Med Hypotheses; 2020 Apr; 137():109564. PubMed ID: 31954994
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How Toll-like receptors influence Parkinson's disease in the microbiome-gut-brain axis.
    Zhang Z; Liu Z; Lv A; Fan C
    Front Immunol; 2023; 14():1154626. PubMed ID: 37207228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Altered gut microbiota and intestinal permeability in Parkinson's disease: Pathological highlight to management.
    Sharma S; Awasthi A; Singh S
    Neurosci Lett; 2019 Nov; 712():134516. PubMed ID: 31560998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Unravelling the role of gut microbiota in Parkinson's disease progression: Pathogenic and therapeutic implications.
    Rani L; Mondal AC
    Neurosci Res; 2021 Jul; 168():100-112. PubMed ID: 33417973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.